Reality Check

MMIT Reality Check on Psoriasis

Payer Coverage: A review of market access for psoriasis treatments shows that under the pharmacy benefit, about 70% of the lives under commercial formularies are covered with utilization management restrictions. Ar...
0 Comments

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Payer Coverage: A review of market access for hemophilia A (factor VIII) treatments shows that under the pharmacy benefit, about 38% of the lives under commercial formularies are covered with utilization management...
0 Comments

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Payer Coverage: A review of market access for diffuse large B-cell lymphoma treatments shows that under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization managem...
0 Comments

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Payer Coverage: A review of market access for multiple sclerosis treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered with utilization management restric...
0 Comments

MMIT Reality Check on Multiple Myeloma (Oct 2021)

Payer Coverage: A review of market access for multiple myeloma treatments shows that under the pharmacy benefit, about half of the lives under commercial formularies are covered with utilization management restrict...
0 Comments

MMIT Reality Check on Sickle Cell Disease (Sept 2021)

Payer Coverage: A review of market access for sickle cell disease treatments shows that under the pharmacy benefit, about 38% of the lives under commercial formularies are covered with utilization management restri...
0 Comments

MMIT Reality Check on Schizophrenia (Sept 2021)

Payer Coverage: A review of market access for schizophrenia treatments shows that under the pharmacy benefit, about 26% of the lives under commercial formularies are covered with utilization management restrictions...
0 Comments

MMIT Reality Check on Acute Migraine (Sept 2021)

Payer Coverage: A review of market access for acute migraine treatments shows that under the pharmacy benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictio...
0 Comments

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2021)

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treatments, combined with news from key healthcare influence...
0 Comments

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2021)

According to our recent payer coverage analysis for non-small cell lung cancer systemic therapy treatments treatments, combined with news from key healthcare influencers, market access is shifting in this drug lands...
0 Comments